Cystic Fibrosis (Respiratory) – Drugs In Development, 2021
- Pages: 545
- Published: July 2021
- Report Code: GMDHC12991IDB
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2021, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.
Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 32, 18, 2, 75, 39 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 1, 6, 8 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
– The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned
4D Molecular Therapeutics Inc
AbbVie Inc
Abeona Therapeutics Inc
Aceragen Inc
Affinia Therapeutics
Agile Sciences Inc
AiCuris AG
Airbase Breathing Co LLC
Airway Therapeutics LLC
Alaxia SAS
AlgiPharma AS
Antabio SAS
Arch Biopartners Inc
Arcturus Therapeutics Holdings Inc
Armata Pharmaceuticals
Arrevus Inc
Arrowhead Pharmaceuticals Inc
Atlantic Healthcare Plc
Avidin Biotechnology Ltd
BioAegis Therapeutics Inc
Biofilm Pharma
Biolytx Pharmaceuticals Corp
BiomX Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Breathe Easy Therapeutics Ltd
BridgeBio Pharma Inc
Calista Therapeutics Inc
Calithera Biosciences Inc
Catabasis Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Cilian AG
Clarametyx Biosciences Inc
ContraFect Corp
Copernicus Therapeutics Inc
CRISPR Therapeutics AG
CrowdOut Therapeutics
CSA Biotechnologies LLC
Cyclacel Pharmaceuticals Inc
Cyclenium Pharma Inc
Daiichi Sankyo Co Ltd
Destiny Pharma Plc
DiscoveryBiomed Inc
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
EmphyCorp Inc
EnBiotix Inc
enGene Inc
Enterprise Therapeutics Ltd
Entrinsic Bioscience Inc
Evaxion Biotech ApS
Evotec SE
Exotect LLC
F. Hoffmann-La Roche Ltd
Feldan Therapeutics Inc
Felix Biotechnology Inc
Galapagos NV
Galenus Therapeutics Inc
Generation Bio Co
Genzyme Corp
Helperby Therapeutics Group Ltd
Horizon Therapeutics Plc
Hunterian Medicine LLC
Icagen Inc
Immun System IMS AB
Insmed Inc
Invion Ltd
Ionis Pharmaceuticals Inc
Kamada Pharmaceuticals
Kither Biotech Srl
Krystal Biotech Inc
Lakewood-Amedex Inc
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
MannKind Corp
Mariposa Health Ltd
Microbion Corp
Mucokinetica Ltd
Nabriva Therapeutics Plc
Nanogenics Ltd
Neupharma Srl
New Amsterdam Sciences Inc
Novabiotics Ltd
Omnispirant Ltd
Orphomed Inc
OrPro Therapeutics Inc
Oryn Therapeutics
Parion Sciences Inc
Pharmaero ApS
PhaseBio Pharmaceuticals Inc
Polyphor Ltd
Progenra Inc
Prolong Pharmaceuticals LLC
Pulmatrix Inc
PureIMS BV
Pylum Biosciences Inc
RAGE Biotech Pty Ltd
Rare Partners Srl
Recode Therapeutics Inc
Renovion Inc
Respirion Pharmaceuticals Pty Ltd
Riptide Bioscience Inc
San Rocco Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
SciBac Inc
Sequoia Sciences Inc
Shape Therapeutics Inc
Silurian Pharmaceuticals Inc
SOLA Biosciences LLC
SolAeroMed Inc
Specific Biologics Inc
Spirovant Sciences Inc
SpliSense Ltd
Synedgen Inc
Synovo GmbH
Synspira Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tavanta Therapeutics Inc
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Translate Bio Inc
Vast Therapeutics Inc
Vectura Group Plc
Vera Therapeutics Inc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
VGSK Technologies Inc
Vironika LLC
Yumanity Therapeutics Inc
Zambon Co SpA
Zata Pharmaceuticals Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.